The funding will take home & clinical tests through clinical trials and submissions for FDA clearance.
The ultimate goal is to 3D print the entire vascular system of a kidney in 12 hours or less.
Prellis is developing ultra-fast high-resolution holographic laser printing for creating human organs and tissues.
The two companies will advance the $1.2 million high-precision Holograph-X Bioprinter
Channel Medsystems has developed the Cerene® Cryotherapy Device to treat heavy menstrual bleeding.
Zenflow's technology relieves urinary blockage caused by enlarged prostate. The funding will accelerate progress to market.
Raydiant was a 2017 Rosenman Innovator.
The biggest opportunity for the 600-person company is to produce entirely new products that are untethered to traditional petroleum-based manufacturing.
Science Magazine profiles Zymergen's AI/robotics technology for microbe engineering.
True North is a Mission Bay Capital portfolio company pursuing therapies that target the complement system to treat rare diseases.
Symic recently graduated from the QB3@953 incubator after several years' residence.
Principia is a spinoff from Jack Taunton’s lab at UCSF.
Principia plans to list on the Nasdaq under the symbol PRNB.
The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology.
eFFECTOR, in Mission Bay Capital's portfolio, is a leader in the development of selective translation regulators for the treatment of cancer.
eFT508 and avelumab are immunotherapies, designed to harness the body's own immune system in fighting cancer.
Atreca uses its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.
Atreca was one of the first companies in Mission Bay Capital’s portfolio.
Atreca was an early portfolio company of QB3-affiliated Mission Bay Capital.
Atreca will apply its Immune Repertoire Capture® technology to generate sequences of native antibodies and TCRs from patients.
Sillajen is a former resident of the Mission Bay Innovation Center.
The collaboration will advance polypharmacology in drug discovery using AI-augmented technology.
The partnership will develop intravitreal gene therapeutics for patients using 4DMT-proprietary AAV vectors.
Graphwear's wearable device employs an ultrathin layer of graphene in its sensor.
The financing will help the company advance its Smart Growth Factor™ pipeline into the clinic.
Modus is a modular 'drop in' technology to monetize refinery offgas streams.
BillionToOne’s first product is a non-invasive prenatal test for recessively inherited single gene disorders.
Wary of failing in public, they worked in stealth at the QB3 Garage for 5 years.
Not many synbio scientists have seen the results of their research onstage at Fashion Week in Paris.
Pivot is partnering with Monsanto, a Bayer company, to help US soybean farmers boost crop harvests.
Pivot’s microbial technology will allow farmers to reduce the use of fertilizers, which can generate potent greenhouse gases.
Pivot’s crop probiotics prevent the nitrate runoff that causes algal blight in waterways.
The funds will accelerate commercialization of pipelined products and expand Lygos’s technology platform.
The competition spotlights technology to convert corn into bio-renewable chemicals.
Lygos’ pilot collaboration is part of a two-year, $5 million, multi-company effort coordinated by the Agile BioFoundry.
In the San Francisco Business Times’s annual survey.
Grifols, based in Spain, is set to acquire a 44% stake in GigaGen, a startup that discovers and develops pre-clinical biotherapeutics.
This will take Carmot's lead Type 2 diabetes drug through clinical proof of concept.
The firms will leverage Carmot’s Chemotype Evolution lead-identification technology.
The Award is sponsored by the Rosalind Franklin Society, whose goal is to support and showcase the careers of eminent women in science.
The Caribou CEO and co-founder spoke at TechCrunch Disrupt about the ethical and legal challenges of CRISPR technology.
The company will grow its team and continue development of its sensory platform to digitally measure taste and smell.
The funding will help develop a novel polymer nanoparticle technology platform for non-viral-based delivery of gene therapeutics.
Newomics will use the funds to expand the team and commercialize its silicon-based multinozzle emitter array technology.
The funding will expand the team, enable clinical trials for Meissa’s investigational vaccine, and support a viral vaccine pipeline.
The Meissa team has developed a live attenuated vaccine with global utility.
Meissa was incorporated through QB3 Startup in a Box.
ViewPoint's technology prevents and treats cataracts and presbyopia.
Trace uses machine learning to analyze soil samples for farmers.
Under its new name, Tierra Biosciences, the company will focus on agricultural and biochemical products.
Mark Cuban and Perlara founder Ethan Perlstein met on Twitter, where they had a conversation about drug pricing.
Novartis invested and partnered with Perlara, a resident of QB3@953, to discover and develop treatments for lysosomal storage disorders using CRISPR-engineered animal models.
The funding will enable the startup to expand its technology's role in discovering therapies for blood cancers and developing gene-editing technologies.
Mission Bio’s machine reads each cell’s DNA—the full blueprint.
The so-called "Harrison rings" were used on five patients.
Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding.
Celgene bought the startup for $300 million upfront to expand its inflammation and immunology pipeline with Delinia's regulatory T cell therapy.
The company will develop new medicines to selectively potentiate and expand regulatory T cells.
Gilead reasons that the companies could treat a broader range of blood and solid cancers.
Asilomar's technology makes plants more efficient at drawing water from the soil.
Last year, Alector advanced two drugs into early-stage clinical testing.
With this much investor interest, the round keeps Alector's options open, CBO Sabah Oney says.
The collaboration could generate up to $225 million for Alector.